Hims & Hers Health, Inc. (NYSE:HIMS) Insider Soleil Boughton Sells 2,503 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 2,503 shares of the firm’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $13.95, for a total transaction of $34,916.85. Following the completion of the sale, the insider now owns 164,363 shares in the company, valued at $2,292,863.85. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Soleil Boughton also recently made the following trade(s):

• On Monday, April 1st, Soleil Boughton sold 2,503 shares of Hims & Hers Health stock. The stock was sold at an average price of $15.65, for a total transaction of $39,171.95.
• On Wednesday, March 13th, Soleil Boughton sold 63,621 shares of Hims & Hers Health stock. The stock was sold at an average price of $15.17, for a total transaction of $965,130.57.
• On Friday, February 9th, Soleil Boughton sold 4,080 shares of Hims & Hers Health stock. The stock was sold at an average price of $10.03, for a total transaction of $40,922.40.
• On Monday, February 12th, Soleil Boughton sold 22,839 shares of Hims & Hers Health stock. The stock was sold at an average price of $10.03, for a total transaction of $229,075.17.

Hims & Hers Health Trading Down 0.6 %

NYSE:HIMS opened at $12.34 on Friday. The company has a fifty day moving average of $13.47 and a 200-day moving average of $9.80. Hims & Hers Health, Inc. has a twelve month low of $5.65 and a twelve month high of $17.16.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, February 26th. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.03. The company had revenue of $246.60 million during the quarter, compared to analyst estimates of $245.84 million. Hims & Hers Health had a negative net margin of 2.70% and a negative return on equity of 7.21%. Hims & Hers Health’s revenue for the quarter was up 47.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.05) EPS. On average, sell-side analysts predict that Hims & Hers Health, Inc. will post 0.1 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms recently commented on HIMS. Guggenheim lifted their target price on shares of Hims & Hers Health from $15.00 to $17.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Tigress Financial lifted their target price on shares of Hims & Hers Health from $14.00 to $15.00 and gave the stock a “buy” rating in a research report on Friday, January 5th. SVB Leerink began coverage on shares of Hims & Hers Health in a research report on Monday, February 26th. They set a “market perform” rating and a $10.00 target price on the stock. Canaccord Genuity Group assumed coverage on shares of Hims & Hers Health in a research report on Wednesday, April 10th. They set a “buy” rating and a $20.00 target price on the stock. Finally, TheStreet upgraded shares of Hims & Hers Health from a “d” rating to a “c” rating in a report on Monday, March 4th. Five investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $14.85.

Institutional Trading of Hims & Hers Health

Several hedge funds have recently modified their holdings of HIMS. Swiss National Bank increased its stake in shares of Hims & Hers Health by 7.9% in the 1st quarter. Swiss National Bank now owns 185,000 shares of the company’s stock valued at $986,000 after acquiring an additional 13,500 shares in the last quarter. Citigroup Inc. increased its stake in shares of Hims & Hers Health by 249.9% in the 1st quarter. Citigroup Inc. now owns 34,718 shares of the company’s stock valued at $185,000 after acquiring an additional 24,796 shares in the last quarter. Ergoteles LLC bought a new stake in Hims & Hers Health during the 1st quarter valued at $949,000. Charles Schwab Investment Management Inc. increased its stake in Hims & Hers Health by 2.5% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 616,214 shares of the company’s stock valued at $3,285,000 after purchasing an additional 14,990 shares in the last quarter. Finally, Northern Trust Corp increased its stake in Hims & Hers Health by 1.3% during the 1st quarter. Northern Trust Corp now owns 253,307 shares of the company’s stock valued at $1,350,000 after purchasing an additional 3,226 shares in the last quarter. Institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.